-+ 0.00%
-+ 0.00%
-+ 0.00%

Johnson & Johnson's Phase 3 Study Evaluating CAPLYTA Met Its Primary And Key Secondary Endpoints

Benzinga·11/10/2026 13:09:08
Listen to the news
  • CAPLYTA improved manic symptoms versus placebo as early as Day 3, with improvement sustained through Week 3 and a safety and tolerability profile consistent with prior studies
    • Two positive Phase 3 studies will support a planned U.S. FDA submission of CAPLYTA for bipolar mania, reinforcing its potential to address both depressive and manic episodes of bipolar disorder